Evaluation of Intravenous and Intraperitoneal Pharmacokinetics of Dalbavancin in Peritoneal Dialysis Patients

Completed · Phase 4

Conditions studied: Infectious Peritonitis

In brief

This study will evaluate the pharmacokinetic properties of dalbavancin when administered as an intravenous infusion and instilled into the peritoneal space in patients who are undergoing peritoneal dialysis. The patients will receive intravenous dalbavancin followed by intensive plasma and peritoneal dialyses fluid sampling. Following a washout phase, the patients will then receive dalbavancin instilled into their peritoneal space followed by the same intensive plasma and peritoneal dialyses fluid sampling.

Key facts

Study ID

NCT02940730

Run by

University of Colorado, Denver

People needed

10

Starts

2017-05-01

Expected to finish

2018-06-18

Last updated by the study team

2021-03-19

Who can join

Age: 18 and older, up to 89. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Age ≥18 to ≤89 years of age
• Actively receiving chronic peritoneal dialysis
• Ability and willingness to provide written informed consent

You may not qualify if…

• Patients currently receiving antimicrobial therapy or have received antibiotic therapy within 14 days prior to study
• Patients with known hypersensitivity reactions to dalbavancin or other glycopeptides
• Prisoners
• Pregnant or breastfeeding women
• Decisionally challenged patients

Where it is running

• University of Colorado Hospital — Aurora, Colorado, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.